Hims & Hers Health (NYSE:HIMS) Price Target Raised to $32.00 at Bank of America

Hims & Hers Health (NYSE:HIMS) had its price objective raised by stock analysts at Bank of America from $30.00 to $32.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Bank of America‘s target price would suggest a potential upside of 4.69% from the company’s previous close.

A number of other research analysts also recently commented on the stock. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Wall Street Zen cut Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. TD Cowen raised their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a research note on Tuesday. Truist Financial raised their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Finally, Canaccord Genuity Group lifted their target price on Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and a consensus price target of $32.57.

Hims & Hers Health Stock Performance

Shares of HIMS traded down $1.20 on Tuesday, reaching $30.57. The company’s stock had a trading volume of 14,617,514 shares, compared to its average volume of 26,759,574. Hims & Hers Health has a 12-month low of $13.74 and a 12-month high of $65.30. The stock has a market capitalization of $7.07 billion, a P/E ratio of -339.69, a PEG ratio of 88.90 and a beta of 2.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The stock’s 50 day simple moving average is $31.94 and its two-hundred day simple moving average is $26.07.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). The business had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. Hims & Hers Health’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.20 earnings per share. Research analysts forecast that Hims & Hers Health will post 0.03 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 7,163 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $36.49, for a total transaction of $261,377.87. Following the sale, the chief financial officer owned 284,321 shares of the company’s stock, valued at approximately $10,374,873.29. The trade was a 2.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Patrick Harrison Carroll sold 23,726 shares of the business’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the sale, the insider directly owned 181,861 shares in the company, valued at $6,365,135. This trade represents a 11.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 83,126 shares of company stock worth $2,711,339. 11.76% of the stock is currently owned by corporate insiders.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Hims & Hers Health by 23.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after purchasing an additional 78,543 shares during the period. Geneos Wealth Management Inc. purchased a new position in Hims & Hers Health during the 1st quarter worth approximately $30,000. EverSource Wealth Advisors LLC raised its position in Hims & Hers Health by 273.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after buying an additional 687 shares during the last quarter. Amundi lifted its stake in Hims & Hers Health by 5.3% during the 2nd quarter. Amundi now owns 10,296 shares of the company’s stock valued at $489,000 after acquiring an additional 522 shares during the period. Finally, California Public Employees Retirement System boosted its holdings in shares of Hims & Hers Health by 9.5% in the 2nd quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock valued at $16,880,000 after acquiring an additional 29,471 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Second-quarter revenue increased 38% year over year to approximately $753.2 million, beating consensus estimates near $699 million. The company also cited strong subscriber growth and broader personalized-care offerings. Hims & Hers raises annual forecast revenue on strong subscriber growth
• Positive Sentiment: Hims & Hers raised its 2026 revenue outlook to $3.1 billion-$3.3 billion from $2.8 billion-$3.0 billion, and projected third-quarter revenue of $880 million-$900 million, above analyst expectations. Hims & Hers Boosts Revenue Target, Swings to Second-Quarter Loss
• Positive Sentiment: Management said artificial intelligence is improving customer engagement, while specialty-care expansion and international growth through Eucalyptus support longer-term demand. Needham raised its price target to $42 from $35 and maintained a Buy rating. HIMS Q2 Earnings Call Focuses on AI and Global Expansion
• Negative Sentiment: The company reported a quarterly loss of about $0.37 per share, substantially worse than the roughly $0.05-$0.07 loss analysts expected and a profit in the year-earlier period. The miss was the primary reason investors sold the stock. Hims & Hers Q2 revenue beat offset by wider-than-expected loss
• Negative Sentiment: Investments in branded GLP-1 weight-loss treatments, restructuring charges and international expansion are pressuring margins. Investors appear concerned that the costly weight-loss strategy could delay sustainable profitability despite rapid revenue growth. Hims & Hers shares slide as costly weight-loss push squeezes margins
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations or alleged breaches of fiduciary duty. These announcements may add reputational and potential litigation risk, although no wrongdoing has been established. Kaplan Fox investor investigation

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.